U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H14O3
Molecular Weight 230.2597
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NAPROXEN

SMILES

C[C@@]([H])(c1ccc2cc(ccc2c1)OC)C(=O)O

InChI

InChIKey=CMWTZPSULFXXJA-VIFPVBQESA-N
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula C14H14O3
Molecular Weight 230.2597
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68009288

Naproxen (naproxen sodium, NAPROSYN®) is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is an anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. The mechanism of action of the naproxen (naproxen sodium, NAPROSYN®), like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

CNS Activity

Curator's Comment:: Naproxen is a potent inhibitor of prostaglandin synthesis in vitro. Naproxen concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models.

Originator

Curator's Comment:: Syntex was integrated into the Roche group in 1994.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NAPROSYN

Approved Use

NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea.

Launch Date

1.95350397E11
Primary
NAPROSYN

Approved Use

NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea.

Launch Date

1.95350397E11
Primary
NAPROSYN

Approved Use

NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea.

Launch Date

1.95350397E11
Primary
NAPROSYN

Approved Use

NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea.

Launch Date

1.95350397E11
Primary
NAPROSYN

Approved Use

NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea.

Launch Date

1.95350397E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
95 μg/L
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NAPROXEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
94 μg/mL
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NAPROXEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1446 μg × h/mL
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NAPROXEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1448 μg × h/mL
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NAPROXEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15 h
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NAPROXEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NAPROXEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12.5 g single, oral
Overdose
Dose: 12.5 g
Route: oral
Route: single
Dose: 12.5 g
Sources: Page: 1102/129
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: 1102/129
Disc. AE: Abdominal pain, Nausea...
AEs leading to
discontinuation/dose reduction:
Abdominal pain
Nausea
Dizziness
Seizures
Metabolic acidosis (severe)
Sources: Page: 1102/129
4 g single, oral
Highest studied dose
Dose: 4 g
Route: oral
Route: single
Dose: 4 g
Sources: Page: p.272
healthy, 20
n = 4
Health Status: healthy
Age Group: 20
Sex: M
Population Size: 4
Sources: Page: p.272
70.4 g single, oral
Overdose
Dose: 70.4 g
Route: oral
Route: single
Dose: 70.4 g
Co-administed with::
alcohol, p.o
Sources: Page: p.103
healthy, 28
n = 1
Health Status: healthy
Age Group: 28
Sex: M
Population Size: 1
Sources: Page: p.103
Disc. AE: Sinus tachycardia, Drowsiness...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia
Drowsiness
Metabolic acidosis
Seizures
Sources: Page: p.103
26 g single, oral
Overdose
Dose: 26 g
Route: oral
Route: single
Dose: 26 g
Sources: Page: p.458
unhealthy, 58
n = 1
Health Status: unhealthy
Condition: Depressive syndrome|Anxiety
Age Group: 58
Sex: F
Population Size: 1
Sources: Page: p.458
Disc. AE: Thrombopenia...
AEs leading to
discontinuation/dose reduction:
Thrombopenia
Sources: Page: p.458
550 mg 2 times / day multiple, oral
Recommended
Dose: 550 mg, 2 times / day
Route: oral
Route: multiple
Dose: 550 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis
Sources: Page: p.1
Disc. AE: Cardiac thrombosis, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Cardiac thrombosis (grade 3-5)
Myocardial infarction (grade 3-5)
Stroke (grade 3-5)
Gastrointestinal disorder NOS (grade 3-5)
Gastrointestinal bleeding (grade 3-5)
Gastrointestinal ulcer (grade 3-5)
Perforation stomach (grade 3-5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Abdominal pain Disc. AE
12.5 g single, oral
Overdose
Dose: 12.5 g
Route: oral
Route: single
Dose: 12.5 g
Sources: Page: 1102/129
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: 1102/129
Dizziness Disc. AE
12.5 g single, oral
Overdose
Dose: 12.5 g
Route: oral
Route: single
Dose: 12.5 g
Sources: Page: 1102/129
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: 1102/129
Nausea Disc. AE
12.5 g single, oral
Overdose
Dose: 12.5 g
Route: oral
Route: single
Dose: 12.5 g
Sources: Page: 1102/129
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: 1102/129
Seizures Disc. AE
12.5 g single, oral
Overdose
Dose: 12.5 g
Route: oral
Route: single
Dose: 12.5 g
Sources: Page: 1102/129
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: 1102/129
Metabolic acidosis severe
Disc. AE
12.5 g single, oral
Overdose
Dose: 12.5 g
Route: oral
Route: single
Dose: 12.5 g
Sources: Page: 1102/129
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: 1102/129
Drowsiness Disc. AE
70.4 g single, oral
Overdose
Dose: 70.4 g
Route: oral
Route: single
Dose: 70.4 g
Co-administed with::
alcohol, p.o
Sources: Page: p.103
healthy, 28
n = 1
Health Status: healthy
Age Group: 28
Sex: M
Population Size: 1
Sources: Page: p.103
Metabolic acidosis Disc. AE
70.4 g single, oral
Overdose
Dose: 70.4 g
Route: oral
Route: single
Dose: 70.4 g
Co-administed with::
alcohol, p.o
Sources: Page: p.103
healthy, 28
n = 1
Health Status: healthy
Age Group: 28
Sex: M
Population Size: 1
Sources: Page: p.103
Seizures Disc. AE
70.4 g single, oral
Overdose
Dose: 70.4 g
Route: oral
Route: single
Dose: 70.4 g
Co-administed with::
alcohol, p.o
Sources: Page: p.103
healthy, 28
n = 1
Health Status: healthy
Age Group: 28
Sex: M
Population Size: 1
Sources: Page: p.103
Sinus tachycardia Disc. AE
70.4 g single, oral
Overdose
Dose: 70.4 g
Route: oral
Route: single
Dose: 70.4 g
Co-administed with::
alcohol, p.o
Sources: Page: p.103
healthy, 28
n = 1
Health Status: healthy
Age Group: 28
Sex: M
Population Size: 1
Sources: Page: p.103
Thrombopenia Disc. AE
26 g single, oral
Overdose
Dose: 26 g
Route: oral
Route: single
Dose: 26 g
Sources: Page: p.458
unhealthy, 58
n = 1
Health Status: unhealthy
Condition: Depressive syndrome|Anxiety
Age Group: 58
Sex: F
Population Size: 1
Sources: Page: p.458
Cardiac thrombosis grade 3-5
Disc. AE
550 mg 2 times / day multiple, oral
Recommended
Dose: 550 mg, 2 times / day
Route: oral
Route: multiple
Dose: 550 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis
Sources: Page: p.1
Gastrointestinal bleeding grade 3-5
Disc. AE
550 mg 2 times / day multiple, oral
Recommended
Dose: 550 mg, 2 times / day
Route: oral
Route: multiple
Dose: 550 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis
Sources: Page: p.1
Gastrointestinal disorder NOS grade 3-5
Disc. AE
550 mg 2 times / day multiple, oral
Recommended
Dose: 550 mg, 2 times / day
Route: oral
Route: multiple
Dose: 550 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis
Sources: Page: p.1
Gastrointestinal ulcer grade 3-5
Disc. AE
550 mg 2 times / day multiple, oral
Recommended
Dose: 550 mg, 2 times / day
Route: oral
Route: multiple
Dose: 550 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis
Sources: Page: p.1
Myocardial infarction grade 3-5
Disc. AE
550 mg 2 times / day multiple, oral
Recommended
Dose: 550 mg, 2 times / day
Route: oral
Route: multiple
Dose: 550 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis
Sources: Page: p.1
Perforation stomach grade 3-5
Disc. AE
550 mg 2 times / day multiple, oral
Recommended
Dose: 550 mg, 2 times / day
Route: oral
Route: multiple
Dose: 550 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis
Sources: Page: p.1
Stroke grade 3-5
Disc. AE
550 mg 2 times / day multiple, oral
Recommended
Dose: 550 mg, 2 times / day
Route: oral
Route: multiple
Dose: 550 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 4.67 uM]
yes [IC50 486 uM]
yes [IC50 5.67 uM]
yes [IC50 85.4 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride.
2000 Sep
Synthesis of some new 1-acylthiosemicarbazides, 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazole-3-thiones and their anti-inflammatory activities.
2001
[Two complex suicidal poisonings with drugs and their medicolegal aspects].
2001
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
2001
Differential regulation of interleukin-1 beta-induced cyclooxygenase-2 gene expression by nimesulide in human synovial fibroblasts.
2001
Nimesulide, a balanced drug for the treatment of osteoarthritis.
2001
Naproxen particle design using porous starch.
2001 Apr
Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets.
2001 Apr
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
2001 Apr
Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts.
2001 Apr
Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
2001 Apr
Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes.
2001 Apr
Uniformly sized molecularly imprinted polymer for (S)-naproxen retention and molecular recognition properties in aqueous mobile phase.
2001 Apr 13
[Acupuncture contra antiphlogistics in acute lumbago].
2001 Apr 20
I'm taking over-the-counter ibuprofen every day for neck pain. Recently, my doctor gave me a prescription for naproxen for my arthritis. Should I be concerned about taking these two together?
2001 Aug
Localization of cyclooxygenase isozymes in cardiovascular tissues of dogs treated with naproxen.
2001 Aug 10
[Liver damage and nonsteroidal anti-inflammatory drugs: case non-case study in the French Pharmacovigilance Database].
2001 Jan-Feb
A possible mechanism of naproxen-induced lipid peroxidation in rat liver microsomes.
2001 Jul
New issues about nitric oxide and its effects on the gastrointestinal tract.
2001 Jul
Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes.
2001 Jul
Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
2001 Jul
Addition of hydrogen bond donating excipients to oil solution: effect on in vitro drug release rate and viscosity.
2001 Jul
Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate.
2001 Jul
Determination of ibuprofen and naproxen in tablets.
2001 Jul
In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium.
2001 Jul-Aug
In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes.
2001 Jun
Determination of naproxen in pharmaceutical preparations by room-temperature phosphorescence. A comparative study of several organized media.
2001 Jun
By the way, doctor. Which drugs cause problems in the sun?
2001 Jun
[Treatment of pain due to unwanted lactation with a homeopathic preparation given in the immediate post-partum period].
2001 Jun
Fixed drug eruption due to naproxen; lack of cross-reactivity with other propionic acid derivatives.
2001 Jun
[The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
2001 Jun
Treatment of de Quervain's disease:role of conservative management.
2001 Jun
Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro.
2001 Jun
Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen.
2001 Jun 15
[Nitric oxide and gastroduodenal damage caused by NSAIDs. Recent findings and clinical implications].
2001 Mar
Synthesis and cyclooxygenase inhibitory properties of novel (+) 2-(6-methoxy-2-naphthyl)propanoic acid (naproxene) derivatives.
2001 Mar
Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy.
2001 Mar
Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs.
2001 Mar
Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7M-beta-CD to HP-beta-CD.
2001 May
Synthesis, in vitro skin permeation studies, and PLS-analysis of new naproxen derivatives.
2001 May
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
2001 May
Nimesulide reduces interleukin-1beta-induced cyclooxygenase-2 gene expression in human synovial fibroblasts.
2001 May
Severe reversible renal failure due to naproxen-associated acute interstitial nephritis.
2001 May
Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care.
2001 May
The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-beta-cyclodextrin.
2001 May
Stereoselective synthesis of (S)-(+)-Naproxen catalyzed by carboxyl esterase in a multicompartment electrolyzer.
2001 May 28
Upper gastrointestinal toxicity of rofecoxib and naproxen.
2001 May 3
Upper gastrointestinal toxicity of rofecoxib and naproxen.
2001 May 3
Isotachophoretic determination of naproxen in the presence of its metabolite in human serum.
2001 May 4
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.
2001 May-Jun
Patents

Sample Use Guides

Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis: 1 tablet of NAPROSYN® (250 mg or 375 mg or 500 mg) twice daily. Acute Gout: The recommended starting dose is 750 mg of NAPROSYN® followed by 250 mg every 8 hours until the attack has subsided.
Route of Administration: Oral
There are data on the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen (Flu-AM1 and Nap-AM1, respectively) with respect to their properties towards fatty acid amide hydrolase (FAAH). Flu-AM1 and Nap-AM1 inhibited FAAH-catalysed hydrolysis of [(3)H]anandamide by rat brain homogenates with IC50 values of 0.44 and 0.74 uM. The corresponding values for flurbiprofen and naproxen were 29 and >100 uM, respectively.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:04:18 UTC 2021
Edited
by admin
on Fri Jun 25 21:04:18 UTC 2021
Record UNII
57Y76R9ATQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NAPROXEN
EP   GREEN BOOK   HSDB   INCI   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN   INCI  
Official Name English
NAPROXEN [USP-RS]
Common Name English
NAPROXEN [GREEN BOOK]
Common Name English
PN400 COMPONENT NAPROXEN
Code English
NAPROXEN [MI]
Common Name English
NAPROXEN [HSDB]
Common Name English
NAPROXEN COMPONENT OF VIMOVO
Common Name English
(+)-(S)-6-METHOXY-.ALPHA.-METHYL-2-NAPHTHALENEACETIC ACID
Systematic Name English
NAPROXEN [INN]
Common Name English
NAPROXEN [USAN]
Common Name English
NAPROSYN
Brand Name English
2-NAPHTHALENEACETIC ACID, 6-METHOXY-.ALPHA.-METHYL-, (S)-
Common Name English
NAPROXEN [VANDF]
Common Name English
NAPROXEN [EP MONOGRAPH]
Common Name English
RS-3540
Code English
VIMOVO COMPONENT NAPROXEN
Common Name English
NAPROXEN [MART.]
Common Name English
NSC-757239
Code English
NAPROXEN [USP MONOGRAPH]
Common Name English
NSC-750183
Code English
NAPROXEN [WHO-DD]
Common Name English
NAPROXEN [INCI]
Common Name English
NAPROXEN [ORANGE BOOK]
Common Name English
NAPROXEN [JAN]
Common Name English
EC-NAPROSYN
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175722
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
CFR 21 CFR 522.1468
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
NDF-RT N0000175721
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-ATC G02CC02
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-VATC QM01AE56
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-VATC QM02AA12
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
NCI_THESAURUS C1323
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-VATC QG02CC02
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
LIVERTOX 668
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-VATC QM01AE52
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-ATC M01AE52
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-ATC M02AA12
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
CFR 21 CFR 520.1468
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-VATC QM01AE02
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-ATC M01AE56
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
WHO-ATC M01AE02
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
NDF-RT N0000000160
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
Code System Code Type Description
LACTMED
Naproxen
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
DRUG BANK
DB00788
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
INN
2979
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
PUBCHEM
156391
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
NCI_THESAURUS
C680
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
HSDB
3369
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
RXCUI
7258
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY RxNorm
IUPHAR
5230
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
MESH
D009288
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
ChEMBL
CHEMBL154
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
DRUG CENTRAL
1883
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
USP_CATALOG
1457301
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M7769
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY Merck Index
FDA UNII
57Y76R9ATQ
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
CAS
22204-53-1
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
EVMPD
SUB09159MIG
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
EPA CompTox
22204-53-1
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
WIKIPEDIA
NAPROXEN
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
ECHA (EC/EINECS)
244-838-7
Created by admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE INACTIVE -> PARENT
Naproxen is extensively metabolized to 6-0-desmethyl naproxen and both parent and metabolites do not induce metabolizing enzymes
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
EXCRETION PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY
Tmax PHARMACOKINETIC FOOD EFFECT
PHARMACOKINETIC
Tmax PHARMACOKINETIC
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC